Picking the right pharma stock is getting harder; so pick a portfolio: 20 stocks with -23% to +22% downsid
For Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or generating a chunk of US revenue can face adverse observations, delayed approvals, or restrictions. Even if the long-term business is intact, the stock can remain under pressure for months. Stock Reports Plus, powered by Refinitiv, is a comprehensive report that evaluates five key components of 4,000+ listed stocks – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardised scores. The simple average of the above-mentioned five component ratings is normally distributed to reach an average score.
For Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or generating a chunk of US revenue can face adverse observations, delayed approvals, or restrictions. Even if the long-term business is intact, the stock can remain under pressure for months. Stock Reports Plus, powered by Refinitiv, is a comprehensive report that evaluates five key components of 4,000+ listed stocks – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardised scores. The simple average of the above-mentioned five component ratings is normally distributed to reach an average score.
What's Your Reaction?
